Reliance Global (EZRA)
Market Price (3/30/2026): $0.1652 | Market Cap: $1.8 MilSector: Financials | Industry: Insurance Brokers
Reliance Global (EZRA)
Market Price (3/30/2026): $0.1652Market Cap: $1.8 MilSector: FinancialsIndustry: Insurance Brokers
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Weak multi-year price returns2Y Excs Rtn is -61%, 3Y Excs Rtn is -101% | Penny stockMkt Price is 0.2 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -9.0 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -73% | |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -12%, Rev Chg QQuarterly Revenue Change % is -21% | |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 39% | |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -25%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -25% | |
| High stock price volatilityVol 12M is 225% | |
| Key risksEZRA key risks include [1] poor financial health and significant cash burn, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -61%, 3Y Excs Rtn is -101% |
| Penny stockMkt Price is 0.2 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -9.0 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -73% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -12%, Rev Chg QQuarterly Revenue Change % is -21% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 39% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -25%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -25% |
| High stock price volatilityVol 12M is 225% |
| Key risksEZRA key risks include [1] poor financial health and significant cash burn, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Immediate and Dilutive Public Offering Post-IPO.
Reliance Global Group (EZRA) priced a public offering of common shares and warrants at $0.27 per unit on January 28, 2026, immediately following its going public on January 27, 2026. This offering closed on January 29, 2026, raising approximately $2 million in gross proceeds. This rapid offering, at the same price as the initial offering, likely contributed to investor concern regarding dilution, a factor historically demonstrated by a 532.1% increase in total shares outstanding over the past year.
2. Continued Financial Losses and Cash Burn.
The company reported a net loss of $7.0 million for 2025, despite an improvement of 22% compared to the previous year. Additionally, commission income decreased by 12.1% to $12.4 million in 2025. Analysis indicates that Reliance Global Group is "quickly burning through cash," which raises concerns about its long-term financial stability and profitability.
Show more
Stock Movement Drivers
Fundamental Drivers
nullnull
Market Drivers
11/30/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| EZRA | ||
| Market (SPY) | -5.3% | -0.1% |
| Sector (XLF) | -10.0% | -22.3% |
Fundamental Drivers
nullnull
Market Drivers
8/31/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| EZRA | ||
| Market (SPY) | 0.6% | -0.1% |
| Sector (XLF) | -10.8% | -22.3% |
Fundamental Drivers
nullnull
Market Drivers
2/28/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| EZRA | ||
| Market (SPY) | 9.8% | -0.1% |
| Sector (XLF) | -7.1% | -22.3% |
Fundamental Drivers
nullnull
Market Drivers
2/28/2023 to 3/29/2026| Return | Correlation | |
|---|---|---|
| EZRA | ||
| Market (SPY) | 69.4% | -0.1% |
| Sector (XLF) | 40.5% | -22.3% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| EZRA Return | - | - | - | - | - | -40% | -40% |
| Peers Return | -27% | -69% | 72% | 53% | -49% | -43% | -83% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -5% | 72% |
Monthly Win Rates [3] | |||||||
| EZRA Win Rate | - | - | - | - | - | 33% | |
| Peers Win Rate | 48% | 23% | 60% | 55% | 42% | 27% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| EZRA Max Drawdown | - | - | - | - | - | -41% | |
| Peers Max Drawdown | -50% | -75% | -10% | -32% | -55% | -46% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -5% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: GSHD, SLQT, EHTH, GOCO, BRO.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/27/2026 (YTD)
How Low Can It Go
EZRA has limited trading history. Below is the Financials sector ETF (XLF) in its place.
| Event | XLF | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -26.9% | -25.4% |
| % Gain to Breakeven | 36.7% | 34.1% |
| Time to Breakeven | 525 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -43.3% | -33.9% |
| % Gain to Breakeven | 76.5% | 51.3% |
| Time to Breakeven | 295 days | 148 days |
| 2018 Correction | ||
| % Loss | -26.1% | -19.8% |
| % Gain to Breakeven | 35.2% | 24.7% |
| Time to Breakeven | 338 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -83.7% | -56.8% |
| % Gain to Breakeven | 515.2% | 131.3% |
| Time to Breakeven | 4,470 days | 1,480 days |
Compare to GSHD, SLQT, EHTH, GOCO, BRO
In The Past
SPDR Select Sector Fund's stock fell -26.9% during the 2022 Inflation Shock from a high on 1/12/2022. A -26.9% loss requires a 36.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Reliance Global (EZRA)
AI Analysis | Feedback
Here are 1-3 brief analogies for Reliance Global (EZRA):
-
Think of it as Rollins (ROL) for insurance agencies, acquiring and managing independent agencies in a fragmented market.
-
A publicly traded aggregator of independent insurance agencies, akin to how Waste Management (WM) acquires and manages local waste collection companies.
AI Analysis | Feedback
```html- Healthcare and Medicare Insurance: Provides insurance products covering health needs and Medicare programs.
- Personal and Commercial Insurance: Offers insurance policies for individuals and businesses to protect against various risks.
- Trucking Insurance: Delivers specialized insurance coverage tailored for the trucking industry.
- Employee Benefits Insurance: Supplies insurance products designed to provide benefits to employees.
AI Analysis | Feedback
Reliance Global Group, Inc. (EZRA) Major Customers
Reliance Global Group, Inc. (EZRA), through its network of wholesale and retail insurance agencies, primarily serves a diverse base of individuals and businesses seeking various insurance products.
The company's customer categories include:
- Individuals: This category encompasses individuals seeking personal lines of insurance, including healthcare, Medicare, and other personal coverage needs.
- Businesses: This category includes various businesses, ranging from small to large enterprises, that require commercial insurance products. This segment covers general commercial insurance, trucking insurance for logistics and transportation companies, and employee benefits insurance packages for their workforces.
AI Analysis | Feedback
nullAI Analysis | Feedback
```htmlEzra Beyman, Chief Executive Officer and Executive Chairman
Ezra Beyman has served as the Chairman and Chief Executive Officer of Reliance Global Group since 2018. Prior to his role at Reliance Global Group, he founded a mortgage company in 1985, which grew to become the third-largest residential mortgage broker in the United States by the early 2000s. Concurrently, he built and managed a substantial real estate portfolio, owning properties across 17 different states. He began acquiring private insurance agencies around 2005, before the company's public listing. Mr. Beyman has also personally invested $5 million into the company.
Joel Markovits, Chief Financial Officer
Joel Markovits is the Chief Financial Officer of Reliance Global Group. He received accelerated restricted stock awards in September 2025, a measure aimed at enhancing executive retention.
Yaakov Beyman, Executive Vice President of Insurance Division
Yaakov Beyman serves as the Executive Vice President of the Insurance Division at Reliance Global Group. He is the son of Ezra Beyman, the Chairman and CEO. In September 2025, he received accelerated restricted stock awards.
Grant Barra, Senior Vice President of Operations
Grant Barra holds the position of Senior Vice President of Operations at Reliance Global Group.
Jonathan Fortman, Vice President of Acquisitions
Jonathan Fortman is the Vice President of Acquisitions for Reliance Global Group.
```AI Analysis | Feedback
The key risks to Reliance Global (symbol: EZRA) are primarily related to its precarious financial health, the inherent challenges and uncertainties of its acquisition-driven growth strategy, and broader market and regulatory pressures.1. Financial Health and Going Concern Risks: Reliance Global Group demonstrates poor financial strength, with a Z-Score indicating distress and a Beneish M-Score suggesting it is unlikely to be a manipulator. The company reported negative revenue growth of -61.4% over the past three years and continues to face profitability challenges, with an operating margin of -66.32% and a net margin of -53.39%. An Altman Z-Score of -4.89 places the company in the distress zone, indicating a potential risk of bankruptcy within two years. Furthermore, the company has less than one year of cash runway, highlighting significant liquidity concerns. The ability to access capital on acceptable terms remains a critical risk.
2. Risks Associated with Acquisition-Driven Growth Strategy: The company's strategy involves an aggressive acquisition approach, initially focused on insurance agencies and more recently expanding into technology-driven businesses through its EZRA International Group and Scale51 operating model. This strategy carries substantial risks, particularly with recent investments like the planned acquisition of a controlling stake in Enquantum Ltd., a post-quantum cybersecurity company. Specific risks include potential delays or failure to consummate transactions, challenges in funding future tranche payments, the possibility of not achieving a controlling equity or board position, and the inherent uncertainties in the development, performance, commercialization, and market adoption of early-stage technology. Integration and execution challenges, along with the risk that anticipated synergies or operational benefits may not be realized, are also significant.
3. Market, Regulatory, and Industry-Specific Risks: As a participant in the insurance industry, Reliance Global Group is exposed to risks from regulatory changes and intense market competition. The company's stock has experienced high volatility. Furthermore, with its expansion into technology and digital assets, the company faces additional market price volatility risks for its digital asset holdings, as well as cybersecurity, regulatory, and data-protection risks, especially pertinent to its new cybersecurity ventures. Compliance with Nasdaq listing requirements also remains a factor.
AI Analysis | Feedback
The clear emerging threat to Reliance Global, operating through traditional wholesale and retail insurance agencies, is the rapid growth and increasing adoption of **Insurtech platforms and direct-to-consumer (DTC) insurance models**. These digital-first companies leverage technology, artificial intelligence, and data analytics to offer insurance products directly to consumers online, often with streamlined processes, competitive pricing, and enhanced convenience, thereby bypassing the need for traditional insurance agents and agencies. This trend mirrors the disruptive forces seen in other industries where digital solutions have disintermediated traditional brick-and-mortar or agent-based services.
AI Analysis | Feedback
Reliance Global Group, Inc. (symbol: EZRA) operates within several significant insurance markets in the United States. The addressable markets for its main products and services in the U.S. are substantial:
- Healthcare and Medicare Insurance: The U.S. health and medical insurance market was valued at approximately USD 1.65 trillion in 2026 and is projected to grow to USD 2.15 trillion by 2031, demonstrating a compound annual growth rate (CAGR) of 5.37%. Another estimate placed the U.S. health insurance market at USD 1.23 trillion in 2024, with an expectation to reach USD 1.77 trillion by 2030, growing at a CAGR of 6.98%. Specifically, the U.S. individual health insurance market was valued at USD 1.6 trillion in 2022 and is anticipated to reach USD 2.54 trillion by 2030, with a CAGR of 6.08%. The Medicare Advantage market in the U.S. is a rapidly expanding segment, with an estimated size of USD 445.97 billion in 2025, projected to grow to USD 1060.03 billion by 2034 at a CAGR of 10.1%. The U.S. Medicare Supplement health insurance market was valued at USD 30.55 billion in 2025 and is projected to reach approximately USD 50.33 billion by 2035, exhibiting a CAGR of 5.10%.
- Personal Insurance: The global personal lines insurance market was valued at USD 1189 billion in 2025 and is expected to reach USD 2176.42 billion by 2033, growing at a CAGR of 7.85%. North America, which includes the U.S., accounted for 38.80% of this global market share in 2025.
- Commercial Insurance: The U.S. commercial insurance market reached USD 294.6 billion in 2024 and is expected to reach USD 489.1 billion by 2033, with a CAGR of 5.20%. Another report estimates the U.S. Commercial Insurance Market at USD 271.93 billion in 2025, projected to grow to USD 416.83 billion by 2035 at a CAGR of 5.47%. North America held the largest revenue share of over 42% in the global commercial insurance market in 2025.
- Trucking Insurance: The global commercial truck insurance market, which includes the U.S. as a significant component, is forecasted to grow from USD 166.99 billion in 2026 to USD 341.03 billion by 2035, at a CAGR of 8.26%. The U.S. commercial truck insurance market covers over 13.5 million registered commercial trucks.
- Employee Benefits Insurance: The U.S. insurance brokerage for employee benefits market was valued at USD 34.74 billion in 2022 and is projected to reach USD 70.11 billion by 2032, with a CAGR of 7.5%. Furthermore, the U.S. employee benefit broker market size was estimated at USD 10.97 billion in 2024 and is predicted to be worth around USD 18.93 billion by 2034, with a CAGR of 5.61%. Healthcare insurance was the leading segment in the global employee benefit broker market, holding 31.5% of the revenue in 2023.
AI Analysis | Feedback
Reliance Global Group, Inc. (NASDAQ: EZRA) is strategically shifting its focus to drive future revenue growth through a combination of technology investments and the continued evolution of its core insurance operations. Over the next 2-3 years, the company is expected to see growth driven by several key initiatives:
- Expansion into Technology-Driven Sectors via Scale51 Initiative and EZRA International Group: Reliance Global Group launched its Scale51 initiative and EZRA International Group in 2025 to acquire and scale high-growth technology companies in cybersecurity, artificial intelligence (AI), fintech, and digital health. As part of this strategy, the company has already invested in Enquantum Ltd., a post-quantum cybersecurity firm, with plans to acquire a majority stake, and has a non-binding term sheet to acquire a majority stake in Scentech Medical, an AI-based diagnostics company. These technology investments are projected to contribute to revenue growth in 2025 and 2026.
- Organic Growth and Expansion of RELI Exchange: The company's insurance and InsurTech operations, particularly the RELI Exchange platform, remain a stable foundation generating commission income. RELI Exchange, a technology-enabled distribution network, has shown significant growth, including a 36% year-over-year increase in property and casualty (P&C) written premium and a 72% increase in health policies for 2025 enrollment. The platform also expanded its partner network by 285% since 2022.
- Strategic Acquisitions within the Insurance Sector: While the company is expanding its technology portfolio, its foundational strategy still involves the acquisition and management of wholesale and retail insurance agencies. The implementation of a "OneFirm" approach, integrating agency operations into a unified, tech-driven platform, suggests that targeted acquisitions within the insurance space will continue to contribute to revenue. For instance, the acquisition of Spetner Associates, nearing completion in late 2024, was anticipated to almost double annual revenue to approximately $28 million.
- Leveraging AI and Data Mining in InsurTech: Reliance Global Group positions itself as an InsurTech pioneer, utilizing artificial intelligence and cloud-based technologies to enhance the efficiency of the insurance agency/brokerage industry. Its proprietary RELI Exchange platform is built on an "AI and data mining backbone." Continuous advancements and broader adoption of its AI-powered platform, Reliaxchange, are expected to drive growth by optimizing operations and expanding market reach.
- Expansion into Cryptocurrency and Blockchain-Enabled Insurance-Linked Assets: In September 2025, Reliance Global Group announced a strategic move into the digital asset and blockchain sector. This initiative includes building a diversified portfolio of leading cryptocurrencies and exploring the tokenization of insurance-linked assets. This novel approach aims to create a new investment class and unlock long-term growth opportunities by leveraging the company's fintech and AI expertise.
AI Analysis | Feedback
Share Repurchases
- In September 2022, Reliance Global Group, Inc. authorized a share repurchase program to buy back up to 3.0 million shares of its outstanding common stock.
Share Issuance
- In January 2026, Reliance Global Group completed a public offering that generated approximately $2.0 million in gross proceeds from the issuance of common stock and warrants, intended for working capital, strategic investments, and general purposes.
- As of December 31, 2025, the company issued 1,098,004 shares for net proceeds of $859,607 under an Equity Line of Credit (ELOC) facility with White Lion Capital.
- During 2025, Reliance Global Group generated approximately $2.2 million in net proceeds from sales under an At-The-Market (ATM) program.
- For its April 2026 Annual Meeting, the company is seeking shareholder approval for a 14,000,000-share increase to its 2025 Equity Incentive Plan and to permit issuances beyond the Nasdaq 19.99% Exchange Cap under an amended equity line with White Lion Capital, increasing the commitment to $50,000,000.
Outbound Investments
- In February 2026, Reliance Global Group completed an initial investment in Enquantum Ltd., a post-quantum cybersecurity firm, for an aggregate purchase price of $2.125 million to acquire a 51% controlling interest over time. The initial 8% stake was acquired by converting a $166,000 secured bridge note and providing additional cash.
- The company launched EZRA International Group and its "Scale51" operating model in January 2026 to pursue majority ownership positions in high-growth technology businesses, including cybersecurity, artificial intelligence, fintech, and digital health sectors.
- In January 2026, Reliance Global Group entered a non-binding term sheet to acquire a majority stake in Scentech Medical, an Israeli diagnostics company focusing on AI-based breath analysis technology.
Capital Expenditures
- Reliance Global Group's average capital expenditure (CapEx AVG 3YRS) for the trailing twelve months ended December 31, 2025, was $29.62K.
- Over the past five years (approximately 2021-2025), the average CapEx AVG 3YRS was $44.59K, with a peak of $54.74K as of September 30, 2024.
Trade Ideas
Select ideas related to EZRA.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | NDAQ | Nasdaq | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | JEF | Jefferies Financial | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | ALAB | Astera Labs | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
| 02272026 | PAYO | Payoneer Global | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
| 02272026 | FOUR | Shift4 Payments | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 1.42 |
| Mkt Cap | 0.1 |
| Rev LTM | 646 |
| Op Inc LTM | 44 |
| FCF LTM | -3 |
| FCF 3Y Avg | -1 |
| CFO LTM | 4 |
| CFO 3Y Avg | 5 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 9.3% |
| Rev Chg 3Y Avg | 14.3% |
| Rev Chg Q | 7.6% |
| QoQ Delta Rev Chg LTM | 2.6% |
| Op Mgn LTM | 2.7% |
| Op Mgn 3Y Avg | 3.9% |
| QoQ Delta Op Mgn LTM | -1.5% |
| CFO/Rev LTM | -1.9% |
| CFO/Rev 3Y Avg | -0.3% |
| FCF/Rev LTM | -3.7% |
| FCF/Rev 3Y Avg | -1.7% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.1 |
| P/S | 0.1 |
| P/EBIT | 0.8 |
| P/E | 1.4 |
| P/CFO | 9.2 |
| Total Yield | 5.9% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -0.3% |
| D/E | 3.4 |
| Net D/E | 1.4 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -17.9% |
| 3M Rtn | -42.4% |
| 6M Rtn | -55.4% |
| 12M Rtn | -72.9% |
| 3Y Rtn | -55.5% |
| 1M Excs Rtn | -9.6% |
| 3M Excs Rtn | -34.5% |
| 6M Excs Rtn | -51.2% |
| 12M Excs Rtn | -85.0% |
| 3Y Excs Rtn | -115.0% |
FDA Approved Drugs Data
Expand for More| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| ANDA217814 | DECITABINE | decitabine | injectable | 12192025 | |||||
| ANDA217453 | AZACITIDINE | azacitidine | powder | 5202025 | |||||
| ANDA211898 | BORTEZOMIB | bortezomib | injectable | 10112022 | |||||
| ANDA211899 | PEMETREXED DISODIUM | pemetrexed disodium | powder | 5252022 | |||||
| ANDA211724 | CAPECITABINE | capecitabine | tablet | 4272020 | |||||
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 03/10/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 07/30/2025 | 10-Q |
| 03/31/2025 | 05/14/2025 | 10-Q |
| 12/31/2024 | 03/07/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 07/25/2024 | 10-Q |
| 03/31/2024 | 05/20/2024 | 10-Q |
| 12/31/2023 | 04/04/2024 | 10-K |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/18/2023 | 10-Q |
| 12/31/2022 | 03/30/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/15/2022 | 10-Q |
| 03/31/2022 | 05/16/2022 | 10-Q |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Fruchtzweig, Ben | Direct | Sell | 7312025 | 2.85 | 26,000 | 74,001 | 107,433 | Form | |
| 2 | Blumenfrucht, Alex | Direct | Sell | 7242025 | 2.90 | 36,249 | 105,245 | 1,405 | Form | |
| 3 | Brickman, Sheldon | Direct | Sell | 7242025 | 2.82 | 15,236 | 43,039 | 136,989 | Form | |
| 4 | Markovits, Joel | Chief Financial Officer | Direct | Sell | 7242025 | 3.00 | 40,534 | 121,602 | 480,807 | Form |
| 5 | Beyman, Yaakov | EXEC VP, INSURANCE DIVISION | Direct | Sell | 7242025 | 3.06 | 20,000 | 61,149 | 215,474 | Form |
Industry Resources
| Financials Resources |
| Federal Reserve Economic Data |
| Federal Reserve |
| FDIC Data |
| American Banker |
| The Banker |
| Banking Technology |
| Insurance Brokers Resources |
| Insurance Business America |
| A.M. Best |
| National Underwriter |
| Insurance News |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.